{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:17:34Z","timestamp":1787843854789,"version":"build-2784847793"},"reference-count":105,"publisher":"eLife Sciences Publications, Ltd","license":[{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008018","name":"Victorian Cancer Agency","doi-asserted-by":"crossref","award":["MCRF18026"],"award-info":[{"award-number":["MCRF18026"]}],"id":[{"id":"10.13039\/100008018","id-type":"DOI","asserted-by":"crossref"}]},{"award":["MCRF18026"],"award-info":[{"award-number":["MCRF18026"]}],"id":[{"id":"https:\/\/ror.org\/0316wrd42","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000951","name":"Cancer Council Victoria","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000951","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/023m51b03","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015539","name":"Australian Government","doi-asserted-by":"crossref","award":["Research Training Program"],"award-info":[{"award-number":["Research Training Program"]}],"id":[{"id":"10.13039\/100015539","id-type":"DOI","asserted-by":"crossref"}]},{"award":["Research Training Program"],"award-info":[{"award-number":["Research Training Program"]}],"id":[{"id":"https:\/\/ror.org\/0314h5y94","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","award":["CE230100001"],"award-info":[{"award-number":["CE230100001"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]},{"award":["CE230100001"],"award-info":[{"award-number":["CE230100001"]}],"id":[{"id":"https:\/\/ror.org\/05mmh0f86","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001026","name":"National Breast Cancer Foundation","doi-asserted-by":"crossref","award":["IIRS-20-094"],"award-info":[{"award-number":["IIRS-20-094"]}],"id":[{"id":"10.13039\/501100001026","id-type":"DOI","asserted-by":"crossref"}]},{"award":["IIRS-20-094"],"award-info":[{"award-number":["IIRS-20-094"]}],"id":[{"id":"https:\/\/ror.org\/0120ky124","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000923","name":"Australian Research Council","doi-asserted-by":"crossref","award":["DP210103074"],"award-info":[{"award-number":["DP210103074"]}],"id":[{"id":"10.13039\/501100000923","id-type":"DOI","asserted-by":"crossref"}]},{"award":["DP210103074"],"award-info":[{"award-number":["DP210103074"]}],"id":[{"id":"https:\/\/ror.org\/05mmh0f86","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":["elifesciences.org"],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Drug resistance inevitably emerges during the treatment of cancer by targeted therapy. Adaptive resistance is a major form of drug resistance, wherein the rewiring of protein signalling networks in response to drug perturbation allows drug-targeted protein activity to recover. This can occur in the continuous presence of the drug and enables cells to survive\/grow. Simultaneously, molecular heterogeneity enables the selection of drug-resistant cancer clones that can survive an initial drug insult, proliferate, and eventually cause disease relapse. Despite their importance, the link between heterogeneity and adaptive resistance, specifically how heterogeneity influences protein signalling dynamics to drive adaptive resistance, remains poorly understood. Here, we have explored the relationship between heterogeneity, protein signalling dynamics, and adaptive resistance through the development of a novel modelling technique coined Meta Dynamic Network (MDN) modelling. We use MDN modelling to characterise how heterogeneity influences the drug-response signalling dynamics of the proteins that regulate early cell cycle progression and demonstrate that heterogeneity can robustly facilitate adaptive resistance associated dynamics for key cell cycle regulators. We determined the influence of heterogeneity at the level of both reaction coefficients and protein abundance and show that reaction coefficients are a much stronger driver of adaptive resistance. Owing to the mechanistic nature of the underpinning ordinary differential equation framework, we then identified a full spectrum of subnetworks capable of driving adaptive resistance dynamics in the key early cell cycle regulators. Finally, we show that single-cell dynamic data supports the validity of our MDN modelling technique and a comparison between our predicted resistance mechanisms and known CDK4\/6 and oestrogen receptor inhibitor resistance mechanisms suggests MDN modelling can be deployed to robustly predict network-level resistance mechanisms for novel drugs and additional protein signalling networks.<\/jats:p>","DOI":"10.7554\/elife.87710","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T10:39:53Z","timestamp":1693564793000},"update-policy":"https:\/\/doi.org\/10.7554\/elife.87710","source":"Crossref","is-referenced-by-count":0,"title":["Systematic analysis of network-driven adaptive resistance to CDK4\/6 and oestrogen receptor inhibition using meta-dynamic network modelling"],"prefix":"10.7554","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-6515","authenticated-orcid":true,"given":"Anthony","family":"Hart","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University","place":["Clayton, Australia"]},{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Biomedicine Discovery Institute, Monash University","place":["Clayton, Australia"]},{"id":[{"id":"https:\/\/ror.org\/028g18b61","id-type":"ROR","asserted-by":"publisher"}],"name":"Computational Systems Oncology Program, South Australian immunoGENomics Cancer Institute (SAiGENCI), The University of Adelaide","place":["Adelaide, Australia"]},{"id":[{"id":"https:\/\/ror.org\/05mmh0f86","id-type":"ROR","asserted-by":"publisher"}],"name":"Australian Research Council Centre of Excellence for the Mathematical Analysis of Cellular Systems (MACSYS)","place":["Parkville, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Sung-Young","family":"Shin","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University","place":["Clayton, Australia"]},{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Biomedicine Discovery Institute, Monash University","place":["Clayton, Australia"]},{"id":[{"id":"https:\/\/ror.org\/028g18b61","id-type":"ROR","asserted-by":"publisher"}],"name":"Computational Systems Oncology Program, South Australian immunoGENomics Cancer Institute (SAiGENCI), The University of Adelaide","place":["Adelaide, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-7705","authenticated-orcid":true,"given":"Lan K","family":"Nguyen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, Nursing and Health Sciences, Monash University","place":["Clayton, Australia"]},{"id":[{"id":"https:\/\/ror.org\/02bfwt286","id-type":"ROR","asserted-by":"publisher"}],"name":"Biomedicine Discovery Institute, Monash University","place":["Clayton, Australia"]},{"id":[{"id":"https:\/\/ror.org\/028g18b61","id-type":"ROR","asserted-by":"publisher"}],"name":"Computational Systems Oncology Program, South Australian immunoGENomics Cancer Institute (SAiGENCI), The University of Adelaide","place":["Adelaide, Australia"]},{"id":[{"id":"https:\/\/ror.org\/05mmh0f86","id-type":"ROR","asserted-by":"publisher"}],"name":"Australian Research Council Centre of Excellence for the Mathematical Analysis of Cellular Systems (MACSYS)","place":["Parkville, Australia"]}],"role":[{"role":"author","vocabulary":"crossref"},{"role":"corresponding-author","vocabulary":"crossref"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"4374","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"bib1","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1073\/pnas.0710887105","type":"journal-article","article-title":"Tamoxifen-stimulated growth of breast cancer due to p21 loss","volume":"105","author":"Abukhdeir","year":"2008","journal-title":"PNAS"},{"key":"bib2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.celrep.2018.12.013","type":"journal-article","article-title":"SHP2 drives adaptive resistance to ERK signaling inhibition in molecularly defined subsets of ERK-dependent tumors","volume":"26","author":"Ahmed","year":"2019","journal-title":"Cell Reports"},{"key":"bib3","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nrc4029","type":"journal-article","article-title":"The mathematics of cancer: integrating quantitative models","volume":"15","author":"Altrock","year":"2015","journal-title":"Nature Reviews. Cancer"},{"key":"bib4","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25422-9","type":"journal-article","article-title":"Co-targeting CDK4\/6 and AKT with endocrine therapy prevents progression in CDK4\/6 inhibitor and endocrine therapy-resistant breast cancer","volume":"12","author":"Alves","year":"2021","journal-title":"Nature Communications"},{"key":"bib5","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","type":"journal-article","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"bib6","doi-asserted-by":"publisher","DOI":"10.1098\/rsif.2017.0237","type":"journal-article","article-title":"How to deal with parameters for whole-cell modelling","volume":"14","author":"Babtie","year":"2017","journal-title":"Journal of the Royal Society, Interface"},{"key":"bib7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2796.2011.02492.x","type":"journal-article","article-title":"Predictive mathematical models of cancer signalling pathways","volume":"271","author":"Bachmann","year":"2012","journal-title":"Journal of Internal Medicine"},{"key":"bib8","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1021\/acs.biochem.5b00621","type":"journal-article","article-title":"The moderately efficient enzyme: futile encounters and enzyme floppiness","volume":"54","author":"Bar-Even","year":"2015","journal-title":"Biochemistry"},{"key":"bib9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174448","type":"journal-article","article-title":"Darwinian approaches for cancer treatment: benefits of mathematical modeling","volume":"13","author":"Belkhir","year":"2021","journal-title":"Cancers"},{"key":"bib10","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1101\/gr.3820805","type":"journal-article","article-title":"Gene expression profiling in single cells from the pancreatic islets of langerhans reveals lognormal distribution of mRNA levels","volume":"15","author":"Bengtsson","year":"2005","journal-title":"Genome Research"},{"key":"bib11","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","type":"journal-article","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discovery"},{"key":"bib12","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1038\/s41592-025-02808-x","type":"journal-article","article-title":"Deep generative modeling of sample-level heterogeneity in single-cell genomics","volume":"22","author":"Boyeau","year":"2025","journal-title":"Nature Methods"},{"key":"bib13","doi-asserted-by":"publisher","first-page":"9817","DOI":"10.1074\/jbc.M010840200","type":"journal-article","article-title":"Phosphatidylinositol 3-kinase\/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance","volume":"276","author":"Campbell","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"bib14","type":"dissertation","article-title":"Studying the Clonal Origins of Drug Resistance in Human Breast Cancers","author":"Cassidy","year":"2019","unstructured":"Cassidy J. 2019. Studying the Clonal Origins of Drug Resistance in Human Breast Cancers. University of Cambridge."},{"key":"bib15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/2159-8290.CD-12-0018","type":"journal-article","article-title":"Negative feedback and adaptive resistance to the targeted therapy of cancer","volume":"2","author":"Chandarlapaty","year":"2012","journal-title":"Cancer Discovery"},{"key":"bib16","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1038\/onc.2015.316","type":"journal-article","article-title":"Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K\/AKT\/HIF-1\u03b1\/cyclin D1 pathway","volume":"35","author":"Chen","year":"2016","journal-title":"Oncogene"},{"key":"bib17","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/j.bbagen.2016.06.009","type":"journal-article","article-title":"Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation","volume":"1860","author":"Chisholm","year":"2016","journal-title":"Biochimica et Biophysica Acta"},{"key":"bib18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41568-020-0258-x","type":"journal-article","article-title":"Executable cancer models: successes and challenges","volume":"20","author":"Clarke","year":"2020","journal-title":"Nature Reviews. Cancer"},{"key":"bib19","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","type":"journal-article","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discovery"},{"key":"bib20","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.20517\/cdr.2019.60","type":"journal-article","article-title":"Network rewiring, adaptive resistance and combating strategies in breast cancer","volume":"2","author":"Cremers","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"bib21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","type":"journal-article","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nature Reviews Clinical Oncology"},{"key":"bib22","doi-asserted-by":"publisher","first-page":"4018","DOI":"10.1038\/onc.2010.154","type":"journal-article","article-title":"Therapeutic CDK4\/6 inhibition in breast cancer: key mechanisms of response and failure","volume":"29","author":"Dean","year":"2010","journal-title":"Oncogene"},{"key":"bib23","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1158\/1078-0432.CCR-18-0410","type":"journal-article","article-title":"MAPK reliance via acquired CDK4\/6 inhibitor resistance in cancerCDK4\/6 inhibitor resistance in cancer","volume":"24","author":"De Leeuw","year":"2018","journal-title":"Clinical Cancer Research"},{"key":"bib24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105241","type":"journal-article","article-title":"PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4\/6 inhibitors in metastatic breast cancer patients","volume":"163","author":"Del Re","year":"2021","journal-title":"Pharmacological Research"},{"key":"bib25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-319-20059-0_1","type":"book-chapter","article-title":"ODE models for systems biological networks","volume-title":"A Guide to Numerical Modelling in Systems Biology","author":"Deuflhard","year":"2015"},{"key":"bib26","type":"software","article-title":"Meta_Dynamic_Analysis_eLife","volume-title":"Software Heritage","author":"DrHartResearch","year":"2026","unstructured":"DrHartResearch. 2026. Meta_Dynamic_Analysis_eLife. Software Heritage. swh:1:rev:c4f3b1c01a41158e230ff6926043b3cce6c60e8b. https:\/\/archive.softwareheritage.org\/swh:1:dir:7c07cc096eaaff5685d74008d177c8dfe07a9d21;origin=https:\/\/github.com\/IntegratedNetworkModellingLab\/Meta_Dynamic_Analysis_eLife;visit=swh:1:snp:6f15a7f571228ff0e72c8f151b6156b113e4a36b;anchor=swh:1:rev:c4f3b1c01a41158e230ff6926043b3cce6c60e8b."},{"key":"bib27","type":"web-resource","article-title":"Palbociclib (IBRANCE)","author":"FDA","year":"2017","unstructured":"FDA. 2017a. Palbociclib (IBRANCE). https:\/\/web.archive.org\/web\/20260201060145\/https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/palbociclib-ibrance [Accessed March 14, 2017]."},{"key":"bib28","type":"web-resource","article-title":"Ribociclib (Kisqali)","author":"FDA","year":"2017","unstructured":"FDA. 2017b. Ribociclib (Kisqali). https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ribociclib-kisqali [Accessed March 14, 2017]."},{"key":"bib29","type":"web-resource","article-title":"FDA approves abemaciclib with endocrine therapy for early breast cancer","author":"FDA","year":"2021","unstructured":"FDA. 2021. FDA approves abemaciclib with endocrine therapy for early breast cancer. https:\/\/web.archive.org\/web\/20250207212208\/https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-abemaciclib-endocrine-therapy-early-breast-cancer [Accessed March 14, 2017]."},{"key":"bib30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09068-2","type":"journal-article","article-title":"Aberrant FGFR signaling mediates resistance to CDK4\/6 inhibitors in ER+ breast cancer","volume":"10","author":"Formisano","year":"2019","journal-title":"Nature Communications"},{"key":"bib31","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","type":"journal-article","article-title":"Next-generation characterization of the cancer cell line encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"bib32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136944","type":"journal-article","article-title":"Feedback, crosstalk and competition: Ingredients for emergent non-linear behaviour in the PI3K\/mTOR signalling network","volume":"22","author":"Ghomlaghi","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"bib33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccell.2016.02.006","type":"journal-article","article-title":"Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4\/6 inhibitors","volume":"29","author":"Goel","year":"2016","journal-title":"Cancer Cell"},{"key":"bib34","doi-asserted-by":"publisher","first-page":"31572","DOI":"10.18632\/oncotarget.25803","type":"journal-article","article-title":"Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer","volume":"9","author":"Haines","year":"2018","journal-title":"Oncotarget"},{"key":"bib35","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-4414","type":"journal-article","article-title":"Abstract 4414: inhibition of CDK2 overcomes primary and acquired resistance to CDK4\/6 inhibitors","volume":"79","author":"Hall","year":"2019","journal-title":"Cancer Research"},{"key":"bib36","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1158\/0008-5472.CAN-18-2711","type":"journal-article","article-title":"A functional landscape of resistance to MEK1\/2 and CDK4\/6 inhibition in NRAS-mutant melanoma","volume":"79","author":"Hayes","year":"2019","journal-title":"Cancer Research"},{"key":"bib37","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","type":"journal-article","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Research"},{"key":"bib38","doi-asserted-by":"publisher","DOI":"10.1186\/s12918-018-0594-6","type":"journal-article","article-title":"RACIPE: a computational tool for modeling gene regulatory circuits using randomization","volume":"12","author":"Huang","year":"2018","journal-title":"BMC Systems Biology"},{"key":"bib39","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.18632\/oncotarget.27127","type":"journal-article","article-title":"The p21 levels have the potential to be a monitoring marker for ribociclib in breast cancer","volume":"10","author":"Iida","year":"2019","journal-title":"Oncotarget"},{"key":"bib40","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s12282-020-01090-3","type":"journal-article","article-title":"Decreased ER dependency after acquired resistance to CDK4\/6 inhibitors","volume":"27","author":"Iida","year":"2020","journal-title":"Breast Cancer"},{"key":"bib41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","type":"journal-article","article-title":"A landscape of pharmacogenomic interactions in cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"bib42","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-16-2653","type":"journal-article","article-title":"Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4\/6 inhibition in ER-positive breast cancer","volume":"77","author":"Jansen","year":"2017","journal-title":"Cancer Research"},{"key":"bib43","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","type":"journal-article","article-title":"Emergence of constitutively active estrogen receptor-\u03b1 mutations in pretreated advanced estrogen receptor-positive breast cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"bib44","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01210-9","type":"journal-article","article-title":"LncRNA TROJAN promotes proliferation and resistance to CDK4\/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer","volume":"19","author":"Jin","year":"2020","journal-title":"Molecular Cancer"},{"key":"bib45","first-page":"3331","type":"journal-article","article-title":"Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer","volume":"55","author":"Johnston","year":"1995","journal-title":"Cancer Research"},{"key":"bib46","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.7150\/thno.64347","type":"journal-article","article-title":"Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes","volume":"12","author":"Jubran","year":"2022","journal-title":"Theranostics"},{"key":"bib47","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.66942","type":"journal-article","article-title":"Akt phosphorylates insulin receptor substrate to limit PI3K-mediated PIP3 synthesis","volume":"10","author":"Kearney","year":"2021","journal-title":"eLife"},{"key":"bib48","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-20769-5","type":"journal-article","article-title":"CDK4\/6 initiates Rb inactivation and CDK2 activity coordinates cell-cycle commitment and G1\/S transition","volume":"12","author":"Kim","year":"2022","journal-title":"Scientific Reports"},{"key":"bib49","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110448","type":"journal-article","article-title":"CDK\/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities","volume":"38","author":"Knudsen","year":"2022","journal-title":"Cell Reports"},{"key":"bib50","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1158\/0008-5472.CAN-20-2275","type":"journal-article","article-title":"Functional determinants of cell cycle plasticity and sensitivity to CDK4\/6 inhibition","volume":"81","author":"Kumarasamy","year":"2021","journal-title":"Cancer Research"},{"key":"bib51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52480-3","type":"journal-article","article-title":"Stochastic and heterogeneous cancer cell migration: experiment and theory","volume":"9","author":"Kwon","year":"2019","journal-title":"Scientific Reports"},{"key":"bib52","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","type":"journal-article","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"key":"bib53","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","type":"journal-article","article-title":"INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discovery"},{"key":"bib54","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.7150\/thno.14409","type":"journal-article","article-title":"Adaptive and acquired resistance to EGFR inhibitors converge on the MAPK pathway","volume":"6","author":"Ma","year":"2016","journal-title":"Theranostics"},{"key":"bib55","doi-asserted-by":"publisher","first-page":"68012","DOI":"10.18632\/oncotarget.12010","type":"journal-article","article-title":"A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer","volume":"7","author":"Malorni","year":"2016","journal-title":"Oncotarget"},{"key":"bib56","doi-asserted-by":"publisher","first-page":"4910","DOI":"10.1158\/0008-5472.CAN-08-0303","type":"journal-article","article-title":"Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor","volume":"68","author":"Masri","year":"2008","journal-title":"Cancer Research"},{"key":"bib57","doi-asserted-by":"publisher","first-page":"8266","DOI":"10.1158\/0008-5472.CAN-05-4045","type":"journal-article","article-title":"Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2\/neu-positive breast cancer","volume":"66","author":"Massarweh","year":"2006","journal-title":"Cancer Research"},{"key":"bib58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jsbmb.2006.09.028","type":"journal-article","article-title":"c-Myc overexpression and endocrine resistance in breast cancer","volume":"102","author":"McNeil","year":"2006","journal-title":"The Journal of Steroid Biochemistry and Molecular Biology"},{"key":"bib59","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1158\/1535-7163.MCT-17-0537","type":"journal-article","article-title":"Combined inhibition of mTOR and CDK4\/6 is required for optimal blockade of E2F function and long-term growth inhibition in estrogen receptor-positive breast cancer","volume":"17","author":"Michaloglou","year":"2018","journal-title":"Molecular Cancer Therapeutics"},{"key":"bib60","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00803-1","type":"journal-article","article-title":"Single-cell transcriptomics reveals biomarker heterogeneity linked to CDK4\/6 Inhibitor resistance in breast cancer cell lines","volume":"11","author":"Migliaccio","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"bib61","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1172\/JCI41680","type":"journal-article","article-title":"Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer","volume":"120","author":"Miller","year":"2010","journal-title":"The Journal of Clinical Investigation"},{"key":"bib62","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2018.04.037","type":"journal-article","article-title":"Cyclin E overexpression confers resistance to the CDK4\/6 specific inhibitor palbociclib in gastric cancer cells","volume":"430","author":"Min","year":"2018","journal-title":"Cancer Letters"},{"key":"bib63","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01642-5","type":"journal-article","article-title":"S6K1 amplification confers innate resistance to CDK4\/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer","volume":"21","author":"Mo","year":"2022","journal-title":"Molecular Cancer"},{"key":"bib64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2025.101300","type":"journal-article","article-title":"A systems view of cellular heterogeneity: Unlocking the \u201cwheel of fate\u201d","volume":"16","author":"Movasat","year":"2025","journal-title":"Cell Systems"},{"key":"bib65","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02872","type":"journal-article","article-title":"Cyclin D activates the Rb tumor suppressor by mono-phosphorylation","volume":"3","author":"Narasimha","year":"2014","journal-title":"eLife"},{"key":"bib66","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.semcdb.2015.09.024","type":"journal-article","article-title":"Feedback regulation in cell signalling: lessons for cancer therapeutics","volume":"50","author":"Nguyen","year":"2016","journal-title":"Seminars in Cell & Developmental Biology"},{"key":"bib67","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01320-8","type":"journal-article","article-title":"Targeting activated PI3K\/mTOR signaling overcomes acquired resistance to CDK4\/6-based therapies in preclinical models of hormone receptor-positive breast cancer","volume":"22","author":"O\u2019Brien","year":"2020","journal-title":"Breast Cancer Research"},{"key":"bib68","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-14-2955","type":"journal-article","article-title":"CDK4 amplification reduces sensitivity to CDK4\/6 inhibition in fusion-positive rhabdomyosarcoma","volume":"21","author":"Olanich","year":"2015","journal-title":"Clinical Cancer Research"},{"key":"bib69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32828-6","type":"journal-article","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nature Communications"},{"key":"bib70","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123566","type":"journal-article","article-title":"Combined CDK2 and CDK4\/6 inhibition overcomes palbociclib resistance in breast cancer by enhancing senescence","volume":"12","author":"Pandey","year":"2020","journal-title":"Cancers"},{"key":"bib71","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.1038\/s41388-020-1255-y","type":"journal-article","article-title":"Feedback analysis identifies a combination target for overcoming adaptive resistance to targeted cancer therapy","volume":"39","author":"Park","year":"2020","journal-title":"Oncogene"},{"key":"bib72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/1541-7786.MCR-17-0602","type":"journal-article","article-title":"Dual inhibition of CDK4 and CDK2 via targeting p27 tyrosine phosphorylation induces a potent and durable response in breast cancer cells","volume":"16","author":"Patel","year":"2018","journal-title":"Molecular Cancer Research"},{"key":"bib73","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.devcel.2022.04.003","type":"journal-article","article-title":"The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma","volume":"57","author":"Patel","year":"2022","journal-title":"Developmental Cell"},{"key":"bib74","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ccell.2022.04.002","type":"journal-article","article-title":"The translational challenges of precision oncology","volume":"40","author":"Pich","year":"2022","journal-title":"Cancer Cell"},{"key":"bib75","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yexmp.2006.09.001","type":"journal-article","article-title":"Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer","volume":"82","author":"Planas-Silva","year":"2007","journal-title":"Experimental and Molecular Pathology"},{"key":"bib76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-1-59745-243-4_14","type":"journal-article","article-title":"Kinetic modeling of biological systems","volume":"541","author":"Resat","year":"2009","journal-title":"Methods in Molecular Biology"},{"key":"bib77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-019-2098-8","type":"journal-article","article-title":"Cisplatin exposure causes c-Myc-dependent resistance to CDK4\/6 inhibition in HPV-negative head and neck squamous cell carcinoma","volume":"10","author":"Robinson","year":"2019","journal-title":"Cell Death & Disease"},{"key":"bib78","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.4161\/cc.3.10.1164","type":"journal-article","article-title":"Oncogenic mutations of PIK3CA in human cancers","volume":"3","author":"Samuels","year":"2004","journal-title":"Cell Cycle"},{"key":"bib79","doi-asserted-by":"publisher","DOI":"10.3390\/cells8030201","type":"journal-article","article-title":"Complex systems biology approach in connecting PI3K-Akt and NF-\u03baB pathways in prostate cancer","volume":"8","author":"Shankar","year":"2019","journal-title":"Cells"},{"key":"bib80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1006192","type":"journal-article","article-title":"Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer","volume":"14","author":"Shin","year":"2018","journal-title":"PLOS Computational Biology"},{"key":"bib81","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.1073\/pnas.95.12.7024","type":"journal-article","article-title":"The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis","volume":"95","author":"Smyth","year":"1998","journal-title":"PNAS"},{"key":"bib82","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature08012","type":"journal-article","article-title":"Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis","volume":"459","author":"Spencer","year":"2009","journal-title":"Nature"},{"key":"bib83","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82196-2","type":"journal-article","article-title":"Benchmarking of numerical integration methods for ODE models of biological systems","volume":"11","author":"St\u00e4dter","year":"2021","journal-title":"Scientific Reports"},{"key":"bib84","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.cels.2021.10.007","type":"journal-article","article-title":"The structure of the human cell cycle","volume":"13","author":"Stallaert","year":"2022","journal-title":"Cell Systems"},{"key":"bib85","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1093\/bib\/bbx065","type":"journal-article","article-title":"Mathematical modeling and computational prediction of cancer drug resistance","volume":"19","author":"Sun","year":"2018","journal-title":"Briefings in Bioinformatics"},{"key":"bib86","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0808-y","type":"journal-article","article-title":"Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer","volume":"17","author":"Takeshita","year":"2018","journal-title":"Molecular Cancer"},{"key":"bib87","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/B978-0-323-89775-4.00007-9","type":"book-chapter","article-title":"Chapter 24 - pathway modeling and simulation analysis","volume-title":"Bioinformatics","author":"Tandon","year":"2022"},{"key":"bib88","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1126\/science.1188308","type":"journal-article","article-title":"Quantifying E. coli proteome and transcriptome with single-molecule sensitivity in single cells","volume":"329","author":"Taniguchi","year":"2010","journal-title":"Science"},{"key":"bib89","doi-asserted-by":"publisher","first-page":"696","DOI":"10.18632\/oncotarget.2673","type":"journal-article","article-title":"Cyclin E1 and RTK\/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS","volume":"6","author":"Taylor-Harding","year":"2015","journal-title":"Oncotarget"},{"key":"bib90","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2009.11.022","type":"journal-article","article-title":"Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC","volume":"17","author":"Turke","year":"2010","journal-title":"Cancer Cell"},{"key":"bib91","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","type":"journal-article","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Research"},{"key":"bib92","doi-asserted-by":"publisher","DOI":"10.1186\/s12915-015-0158-9","type":"journal-article","article-title":"Models in biology: lessons from modeling regulation of the eukaryotic cell cycle","volume":"13","author":"Tyson","year":"2015","journal-title":"BMC Biology"},{"key":"bib93","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.jtbi.2018.11.034","type":"journal-article","article-title":"Modeling the dynamic behavior of biochemical regulatory networks","volume":"462","author":"Tyson","year":"2019","journal-title":"Journal of Theoretical Biology"},{"key":"bib94","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","type":"journal-article","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"bib95","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/onc.2011.483","type":"journal-article","article-title":"Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-\u03b1","volume":"31","author":"Vesuna","year":"2012","journal-title":"Oncogene"},{"key":"bib96","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.3390\/ijms15033507","type":"journal-article","article-title":"HBx protein promotes oval cell proliferation by up-regulation of cyclin D1 via activation of the MEK\/ERK and PI3K\/Akt pathways","volume":"15","author":"Wang","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"key":"bib97","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2019.10","type":"journal-article","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resistance"},{"key":"bib98","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071538","type":"journal-article","article-title":"Mechanisms of resistance to PI3K inhibitors in cancer: adaptive responses, drug tolerance and cellular plasticity","volume":"13","author":"Wright","year":"2021","journal-title":"Cancers"},{"key":"bib99","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5732\/cjc.011.10326","type":"journal-article","article-title":"Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology","volume":"31","author":"Xue","year":"2012","journal-title":"Chinese Journal of Cancer"},{"key":"bib100","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22506-3","type":"journal-article","article-title":"Computational methods for estimating molecular system from membrane potential recordings in nerve growth cone","volume":"8","author":"Yamada","year":"2018","journal-title":"Scientific Reports"},{"key":"bib101","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1038\/onc.2016.379","type":"journal-article","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"key":"bib102","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.44571","type":"journal-article","article-title":"Stress-mediated exit to quiescence restricted by increasing persistence in CDK4\/6 activation","volume":"9","author":"Yang","year":"2020","journal-title":"eLife"},{"key":"bib103","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00496-y","type":"journal-article","article-title":"Integrative modeling uncovers p21-driven drug resistance and prioritizes therapies for PIK3CA-mutant breast cancer","volume":"8","author":"Yip","year":"2024","journal-title":"NPJ Precision Oncology"},{"key":"bib104","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0709662105","type":"journal-article","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"PNAS"},{"key":"bib105","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1148792","type":"journal-article","article-title":"CDK4\/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective","volume":"11","author":"Zhou","year":"2023","journal-title":"Frontiers in Cell and Developmental Biology"}],"container-title":["eLife"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.elifesciences.org\/articles\/87710\/elife-87710-v1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/cdn.elifesciences.org\/articles\/87710\/elife-87710-v1.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/elifesciences.org\/articles\/87710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:20:46Z","timestamp":1787840446000},"score":1,"resource":{"primary":{"URL":"https:\/\/elifesciences.org\/articles\/87710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,27]]},"references-count":105,"alternative-id":["10.7554\/eLife.87710"],"URL":"https:\/\/doi.org\/10.7554\/elife.87710","archive":["CLOCKSS"],"relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.24.525460","asserted-by":"subject"}],"is-same-as":[{"id-type":"doi","id":"10.7554\/eLife.87710.3","asserted-by":"subject"}],"is-version-of":[{"id-type":"doi","id":"10.7554\/eLife.87710.1","asserted-by":"subject"},{"id-type":"doi","id":"10.7554\/eLife.87710.2","asserted-by":"subject"}],"is-supplemented-by":[{"id-type":"uri","id":"https:\/\/archive.softwareheritage.org\/swh:1:dir:7c07cc096eaaff5685d74008d177c8dfe07a9d21;origin=https:\/\/github.com\/IntegratedNetworkModellingLab\/Meta_Dynamic_Analysis_eLife;visit=swh:1:snp:6f15a7f571228ff0e72c8f151b6156b113e4a36b;anchor=swh:1:rev:c4f3b1c01a41158e230ff6926043b3cce6c60e8b","asserted-by":"subject"}]},"ISSN":["2050-084X"],"issn-type":[{"value":"2050-084X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,27]]},"assertion":[{"value":"single anonymised","name":"peer_review_transparency","label":"Peer review transparency","group":{"name":"peer_review_taxonomy"}},{"value":"other reviewer(s), editor","name":"peer_review_interaction","label":"Peer review interaction","group":{"name":"peer_review_taxonomy"}},{"value":"review summaries, review reports, author\/editor communication, reviewer identities reviewer opt in, editor identities","name":"peer_review_published","label":"Peer review published","group":{"name":"peer_review_taxonomy"}},{"value":"open (sign in with ORCID iD required)","name":"post_publication_commenting","label":"Post publication commenting","group":{"name":"post_publication_commenting"}}],"article-number":"RP87710"}}